Back Hepatitis C

Hepatitis C

FDA Approves Zepatier (Grazoprevir/Elbasvir) for Hepatitis C Genotypes 1 and 4

The U.S. Food and Drug Administration (FDA) this week announced its approval of Merck's Zepatier -- a once-daily coformulation containing the hepatitis C virus (HCV) protease inhibitor grazoprevir and NS5A inhibitor elbasvir -- for the treatment of HCV genotypes 1 and 4. In several Phase 3 studies grazoprevir/elbasvir taken for 12 weeks demonstrated cure rates exceeding 90% for various groups including people with liver cirrhosis, HIV/HCV coinfected patients, and people who inject drugs.

alt

AbbVie Opens Global Phase 3 Studies of ABT-493/ABT-530 Hepatitis C Regimen

AbbVie has started enrollment of a projected 1600 participants in 6 new international Phase 3 clinical trials evaluating a once-daily regimen of its investigational NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 for people with hepatitis C virus (HCV) genotypes 1 through 6, the company recently announced.

alt

Hepatitis C Linked to Increased Risk of Parkinson's Disease, Studies Show

People with hepatitis C virus (HCV) infection may be more likely to develop Parkinson's disease, especially when combined with other risk factors, though the reason for the association is not fully understood, according to a pair of recently published studies from Taiwan.

alt

Cardiovascular Disease Risk Is Higher for People with Hepatitis C

People with hepatitis C are at higher risk of dying from cardiovascular disease, having a stroke, or developing other cardiovascular problems than people with similar risk factors for heart disease who do not have hepatitis C, a meta-analysis of published studies has shown. The findings, published in the January 2016 edition of Gastroenterology, come from a meta-analysis of 22 epidemiological studies conducted in Italy.

alt

3. Better Options for Treating HCV Genotype 3 and Advanced Liver Disease

This year saw the emergence of new and better treatment options for people with hepatitis C virus (HCV) genotypes other than 1 and for those with advanced liver disease.

alt

AASLD 2015: 3-Drug Combos for 8 Weeks Demonstrate High Hepatitis C Cure Rate

An interferon-free regimen containing Merck's grazoprevir, the NS5A inhibitors elbasvir or MK8404, and the experimental nucleotide polymerase inhibitor MK-3682, taken for 8 weeks, cured more than 90% of non-cirrhotic hepatitis C patients with HCV genotypes 1, 2, or 3, according to late-breaking research presented at the AASLD Liver Meeting in November.

alt

Sofosbuvir/Daclatasvir Combination Could Be Produced for $200 per Hepatitis C Cure

Month-by-month tracking of the prices paid in India for the chemicals used to make direct-acting antivirals to treat hepatitis C shows that it is now possible to make and sell a combination of drugs to cure hepatitis C virus (HCV) infection for less than $200, Andrew Hill of Liverpool University said at the Second European HIV Hepatitis Co-infection Conference in London last week.

alt

New Drugs Could Halt U.S. Hepatitis C Epidemic, but Only with Increased Testing and Treatment

Treatment using direct-acting antiviral agents (DAAs) could have a major impact on the hepatitis C virus (HCV) epidemic in the U.S., according to a model published in the November 30 online edition of Clinical Infectious Diseases. A 4-fold increase in treatment rates could prevent over a quarter of a million HCV-related deaths by 2040, and prevalence could be reduced by 90% with the scale up of screening efforts, especially targeting people who inject drugs (PWID). But the investigators caution that elimination of the epidemic with DAAs would require near-universal testing and a 20% annual treatment rate.

alt

AASLD 2015: U.S. Faces Biggest Burden of Hepatitis C Treatment Costs Before 2020

The cost of treating hepatitis C is likely to decline dramatically over the next decade in the U.S., not because of cuts in drug prices, but because the population in need of treatment will shrink by 2020 as a majority of patients will already have been treated, according to research by Jagpreet Chhatwal of Massachusetts General Hospital and colleagues presented at the AASLD Liver Meeting in San Francisco last month.

alt